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esponsibility of InstAbstract This review focuses on various components of bile acid signaling in relation to cholangio-
cytes. Their roles as targets for potential therapies for cholangiopathies are also explored. While many
factors are involved in these complex signaling pathways, this review emphasizes the roles of
transmembrane G protein coupled receptor (TGR5), farnesoid X receptor (FXR), ursodeoxycholic acid
(UDCA) and the bicarbonate umbrella. Following a general background on cholangiocytes and bile acids,
we will expand the review and include sections that are most recently known (within 5–7 years) regarding
the ﬁeld of bile acid signaling and cholangiocyte function. These ﬁndings all demonstrate that bile acids
inﬂuence biliary functions which can, in turn, regulate the cholangiocyte response during pathological
events.
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Cholangiocytes are a variable group of epithelial cells which line the
biliary epithelium, a three-dimensional network of ducts responsible for
bile acid transport and ductal bicarbonate secretion1,2. Cholangiocytes
are found in both intrahepatic and extrahepatic bile ducts with size,
number and histological type varying based on the size and location of
the ducts. In small bile ducts, which are deﬁned as having a lumen
diameter less than 15 μm, cholangiocytes are either ﬂattened or
cuboidal. In large bile ducts, deﬁned as having a lumen diameter
greater than 15 μm, cholangiocytes are columnar and signiﬁcantly
more abundant3,4. Cholangiocytes contain multiple transporters on both
their apical and basolateral plasma membranes, which assist in
modifying bile acids via both secretion and absorption5. As bile ﬂows
through the duct, the primary cilium on the cholangiocyte apical
membranes senses the ﬂow via mechanoreceptors1. This is partly due
to the expression of polycystin-1 (PC-1) on the primary cilium. Intra-
cholangiocyte Ca2þ levels also increase in response to ﬂow due to
PC-21. Modiﬁcation of the primary bile involves secretion of water,
Cl and HCO3
 into the duct, and extraction of glucose, bile acids and
amino acids. This is accomplished via several transporters, channels
and exchangers, which act based upon the content of the bile and
intracellular space1,6. These modiﬁed bile acids are then delivered to
the duodenum to be further metabolized by enteric bacteria, or returned
to the hepatocytes via the cholehepatic shunt.
Cholangiocytes and bile acid signaling have become a topic of
increasing interest due to their roles in the immune defense. The
secretion of bicarbonate and other molecules creates the bicarbonate
umbrella on the apical membrane of cholangiocytes, which makes
cholangiocytes less susceptible to injury and subsequent apoptosis7,8.
A main component of the bicarbonate umbrella is the peptide, secretin.
Cholangiocytes are the sole cell type in the liver that express secretin
receptor (SR) which, when activated, leads to an opening of the
chloride bicarbonate (Cl/HCO3
) exchanger9. In fact, when animals
are infused with secretin they produce increased amounts of bile and
bicarbonate demonstrating that secretin is a key player in the regulation
of cholangiocyte-induced bile modiﬁcation9,10. Further, previous
studies have linked bile acids and cholangiocytes by demonstrating
that bile acid treatment inﬂuences cholangiocyte proliferation and bile
ﬂow. Numerous studies from Alpini et al.11–13 showed that speciﬁc bile
acids like taurocholic acid (TCA) and taurolithocholic acid stimulate
cholangiocyte proliferation, bicarbonate secretion and bile ﬂow.
While once thought to be a type of dormant, passive cells,
cholangiocytes are now recognized to be active, hormone-responsive
cells that are the target of biliary pathologies known collectively as
cholangiopathies14–16. Numerous studies have indicated that targeting
of cholangiocytes may lead to new therapies for cholangiopathies,
especially primary sclerosing cholangitis (PSC) and primary biliary
cirrhosis (PBC)1,6,7,17,18. PSC and PBC are both end-stage cholangio-
pathies that, if left untreated, are likely to develop into the primary liver
cancer, cholangiocarcinoma19. It is known that cholangiocytes express
adhesion molecules, which are hormone-responsive, secrete inﬂamma-
tory mediators and immunoglobulins, and can act as antigen presenting
cells. These functions have the potential to create beneﬁcial effects for
both adaptive and innate immunity, and also to provide potential
therapeutic advances for patients suffering from cholangiopathies.2. Bile acids
Bile acids are cholanic acid derivatives, which share the chemical
structure of steroids20. They act as detergents and are responsiblefor facilitating the absorption of dietary lipids and fat-soluble
vitamins, and for maintaining cholesterol homeostasis in the body.
Secretion of bile is mediated by secretin, which is released by S
cells in the duodenum and jejunum in response to a meal1,18. The
formation of bile acids is initiated in hepatocytes. Classic and
alternative pathways can be initiated by cholesterol 7α-hydroxylase
(CYP7A1)20. Initially, bile composed primarily of water and various
ions, and solutes is released into bile canaliculi via the apical side of
hepatocytes. The bile acids ﬂow through the canals of Hering before
continuing through the biliary epithelium, where they are subse-
quently modiﬁed primarily by cholangiocytes1,20. Large cholangio-
cytes are thought to play the primary role in this process, but small
cholangiocytes may also contribute to some extent1. After modi-
ﬁcation by cholangiocytes, bile acids are stored in the gallbladder
and most are then secreted into the duodenum where they are
metabolized by enteric bacteria. Approximately 95% of these bile
acids are absorbed in the terminal ileum, and are then transported
back to the liver via the portal vein for recycling20. These
conjugated bile acids will be secreted back into the bile pool. This
process is known as the enterohepatic shunt. However, unconju-
gated bile acids are absorbed by cholangiocytes and returned to the
hepatocytes via the peribiliary vascular plexus in a process known
as the cholehepatic shunt1. The cations found in bile are primarily
calcium, sodium and potassium, while the anions are chloride and
bicarbonate. Bile contains several things, which are found naturally
throughout the body, including lipids, carbohydrates, vitamins,
minerals and proteins20. After synthesis, bile acids are conjugated
with either glycine or taurine, which decreases the toxicity of bile
and makes it more soluble. This is important for the relationship
among cholangiocytes, bile acids and bile acid signaling.3. Transmembrane G protein coupled receptor (TGR5)
TGR5 is a G-protein coupled receptor, which is activated in
response to bile acids. It transmits bile acid signals via the cAMP-
signaling pathway in various cells throughout the body. While our
focus is on its activity in relation to cholangiocytes, it can also be
found in macrophages of the liver (Kupffer cells), intestine, lung
and peritoneum, epithelial cells of the intestine and CD14 positive
monocytes in peripheral blood6,21. Overall, the highest levels of
expression are found in the gallbladder and intestine. There are no
studies that indicate the functional signiﬁcance of the diverse
localization of TGR5 throughout the body and cholangiocytes.
TGR5 is found in many areas of the cholangiocyte, including the
apical plasma membrane, primary cilia and multiple locations in
the intracellular space. While TGR5 is most highly expressed on
the outer and inner nuclear membranes of the cholangiocyte
intracellularly, one study noted that it could also be found in
multivesicular bodies, intracellular vesicles and endoplasmic
reticulum21. However, in addition to the nuclear membrane,
TGR5 is highly expressed on the apical plasma membrane and
cilia21. This ﬁnding is signiﬁcant because activation of TGR5 has
also been shown to contribute to the formation of the bicarbonate
umbrella located on the apical surface of cholangiocytes6.
Cholangiocyte cilia have been determined to have mechano-
receptive, chemoreceptive and osmosensory properties. It is
important to note that not all cholangiocytes have a primary
cilium, and this presumably inﬂuences the different effects that
TGR5 activation has on cholangiocytes. This further supports the
idea that TGR5 has a strong effect at the apical membrane. It has
been shown that the presence of cilia is a result of a longer
Figure 1 Working model of TGR-mediated bile acid signaling in
nonciliated and ciliated cholangiocytes. The localization of TGR5 on
the plasma membrane (PM) or ciliary membrane determines the
cholangiocyte functional response to bile acid (BA) signaling. In
nonciliated cholangiocytes, TGR5 agonists increase cAMP levels and
cell proliferation but inhibit ERK signaling. In ciliated cholangiocytes,
the effects of TGR5 agonists are opposite, i.e., cAMP levels and cell
proliferation decreased, but ERK signaling is activated. Reprinted with
permission from Masyuk et al.21.
Bile acids and cholangiocytes 125duration of cell growth21. Studies using TGR5 agonists such as
taurolithocholic acid, lithocholic acid, oleanolic acid and cholic
acid were used to identify these differences21. The presence or
absence of cilia has also been determined to have an effect on
cellular proliferation. This was validated by demonstrating that
suppression of apical sodium bile acid transporter (ASBT), a
transporter with signiﬁcant involvement in cholangiocyte prolif-
eration, has no effect on the inhibitory effects induced by TGR5
agonists on ciliated cholangiocyte proliferation21.
In ciliated cholangiocytes, TGR5 binds to a Gαi protein, which
is found at the base of the cilia. This results in a decrease in cAMP
signaling, which suggests that an inhibitory signaling pathway
exists in ciliated cholangiocytes in response to stimuli, such as bile
ﬂow21. It has also been shown that this mechanism is associated
with decreased proliferation in ciliated cells in response to TGR5.
It is also important to note that ciliated cholangiocytes contain
more TGR5, Gαi and Gαs than non-ciliated cells. Experiments
involving mitogen-activated protein kinase (MAPK), also known
as extracellular regulated protein kinases (ERK), have demon-
strated a positive relationship between TGR5 signaling and MAPK
activation21. This is of particular interest because of the association
of defects in the MAPK pathway with a variety of cancers.
In non-ciliated cholangiocytes, TGR5 binds to a Gαs protein.
This relationship has been studied more than that of TGR5 and
Gαi proteins. Binding to this G protein leads to an increase in
cAMP signaling, suggesting that there is a stimulatory relationship
between TGR5 and non-ciliated cholangiocyte cells21. As opposed
to the effect of TGR5 on ciliated cholangiocytes, the binding to
non-ciliated cholangiocytes leads to increased cellular prolifera-
tion. In contrast to ciliated cholangiocytes, TGR5 in non-ciliated
cholangiocytes inhibits MAPK activation, which also makes it
especially interesting for certain ﬁelds of cancer research. To date,
no studies have demonstrated what mechanisms affect the binding
of TGR5 to different Gα proteins21.
Because TGR5 inhibits the secretion and expression of cytokines
in immune cells, it has been studied as a potential target for
immune-mediated cholangiopathies. Other protective qualities of
TGR5 include the prevention of apoptosis and secretion of
components of the bicarbonate umbrella. Such mechanisms have
led to the idea that TGR5 agonists could be helpful in diseases such
as PSC, which involve inﬂammatory changes within the biliary tree.
One study demonstrated that, while the activation of TGR5 led to
decreased systemic inﬂammation and enhanced cholangiocyte
protection, it did not improve PSC in mice6. However, it was noted
to increase cholestatic-induced pruritus. It was also noted that the
lack of TGR5 activation increased inﬂammatory hepatic inﬁltrates,
but decreased the incidence of cholesterol gallstones6. Mutations in
the coding region of TGR5, such as 2q35, have been found in
patients with PSC and ulcerative colitis, but have not been found to
enhance one's susceptibility to these diseases. While the primary
source of injury in PSC is yet to be determined, one concept
involves gut-derived inﬂammatory leakage. This is secondary to the
absence of the ABCB4 (ATP-binding cassette, sub-family B)
phospholipid transporter, which results in a lack of phospholipids
in bile. This allows bile acids to leak across tight junctions and
initiate inﬂammatory damage. Gut-derived lymphocytes have been
found in the portal inﬁltrate of patients with PSC6. Support for this
concept stems from the fact that PSC is frequently associated with
IBD, and that proctocolectomy has been shown to reduce the
recurrence of PSC after liver transplantation for this illness6.
While the activation of TGR5 has many beneﬁcial effects, it can
also lead to detrimental outcomes. Because of its pro-proliferationand anti-apoptotic properties, it has been implicated as a con-
tributing factor in the pathogenesis of several gastrointestinal
tumors, including cholangiocarcinoma and colorectal cancer6.
One study noted that TGR5 was highly expressed in human
cholangiocarcinoma samples taken from patients who did not have
PSC6. A summary ﬁgure of TGR5 signaling is found in Fig. 1.
While TGR5 has the potential to offer new and beneﬁcial
alternatives for patients with cholangiopathies, further studies are
needed, not only to explore potential negative effects but also to
demonstrate speciﬁc mechanisms by which it can be utilized.4. Farnesoid X receptor (FXR)
Due to their location, cholangiocytes are able to modify bile quickly
and efﬁciently as it travels through the biliary tree. FXR is a nuclear
receptor, encoded by NR1H4, which is found in the liver and
intestines22. Bile acids, speciﬁcally hydrophobic bile acids, act as
ligands for this receptor and utilize it in their negative feedback loop17.
Fibroblast growth factor 19, which is highly expressed in human
cholangiocytes, is activated by FXR. This activation, via ﬁbroblast
growth factor receptor 4, leads to the repression of cholangiocyte sterol-
27-hydroxylase (CYP27), which is the rate-limiting enzyme in the
acidic pathway of bile acid synthesis17. While it was determined that
p38 kinase inhibitor is not directly involved in the repression of
CYP27, it has been shown to be an important mediator of the ﬁbroblast
growth factor 19 (FGF19) signal via the ability to down-regulate
FXR17,23. Inhibition of CYP27 prevents the basolateral cholesterol
efﬂux mediated by liver X receptor and 27-hydrocholesterol, the
product of Cyp27, in the cholangiocyte17. FXR has also been noted to
have paracrine effects. While it is known that bile acids can inhibit
hepatocyte CYP27, a recent study also demonstrated that bile acids
have the ability to repress hepatocyte CYP7A1 via the cholangiocyte
FXR/FGF pathway17,24. This leads to a reduction in bile acid by the
liver24. Studies have shown that defects in FXR, and its associated
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importance of the cholangiocyte in bile acid modiﬁcation.
Several studies have demonstrated the protective effects of FXR
in relation to liver transplantation23,24. This is a topic of interest
due to the complications, such as nonanastomotic strictures, which
can result from bile acid toxicity post-transplant. Many such
injuries are the result of hypoxia and ischemia, which are
unavoidable components of the procedure. It has been shown that
FXR is repressed in the setting of hypoxia and ischemia post-
transplant23. However, the release of inﬂammatory cytokines post-
transplant has also been shown to decrease the expression of
FXR23. While it is not the sole factor, the down-regulation of FXR
is a contributing cause in biliary epithelial damage due to the
associated disturbance in bile acid transport. Hypoxia induces the
repression of FXR via p38, leading to changes in bile acid
transporters17,23. ASBT, a transporter located on the apical surface
of cholangiocytes, is slightly down-regulated by FXR. When
levels of FXR are reduced, the expression of this transporter is
increased, leading to enhanced absorption of bile acids into the
cholangiocyte. In addition, the activity of organic solute transpor-
ter α/β (OSTα/β), one transporter responsible for basolateral efﬂux
of bile acids, is reduced in response to lower levels of FXR. These
factors lead to an unbalanced accumulation of intracellular bile
acids and have been shown to enhance apoptosis and the
expression of proﬁbrotic factors. Increased biliary transit time is
associated with enhanced bile duct injury, and has been linked to
reduced levels of FXR23. The demonstrated capacity of bile acid
signaling to induce toxic effects and cellular disruption suggests a
possible role in the development of cholangiopathies.
The hepato-protective effects of FXR can also be noted in the
setting of partial hepatectomy. In this setting, it is particularly important
to control the level of bile acid synthesis in order to reduce bile acid
induced toxicity. FGF19 down-regulates CYP7A1 expression, thereby
preventing cellular injury via the suppression of bile acid synthesis.
One study demonstrated that the reduction of FXR, and thereby FGF15
expression in mice, led to a signiﬁcantly high mortality after partial
hepatectomy24. It was also noted that mice deﬁcient in FGF15 activity
had a higher mortality overall24. In addition to regulation of bile acid
synthesis, FGF stimulation enhances the expression of hepatocyte
growth factor (HGF), a regenerative growth factor, and decreases levels
of some inﬂammatory chemokines. While HGF and EGF are known to
be mitogens in terms of liver growth, studies have demonstrated that
FGF19 can act as a growth factor for hepatocytes and cholangiocytes,
and promote wound healing in the biliary system24. FGF19 acts on the
MAPK/ERK1/2 pathway to stimulate proliferation of hepatocytes and
cholangiocytes. Measured growth via this pathway was found to be
comparable to that induced by more established growth factors24. In
addition to these ﬁndings, it was also noted that mice lacking Fgf15 did
not demonstrate the expected amount of liver growth in response to
cholic acid feeding. This data was veriﬁed using a human hepatocyte
cell line. These ﬁndings suggest a possible role for FGF19 in the
setting of liver transplant, in which the administration could prevent
cholestasis and the detrimental effects associated with it.5. Ursodeoxycholic acid (UDCA) and the bicarbonate
umbrella
UDCA is a hydrophilic bile acid found in small amounts in
humans. It is the target of many studies due to its therapeutic
potential, and is considered a ﬁrst line treatment for primary biliary
cirrhosis18,25. Accumulation of hydrophobic bile acids in thesetting of cholestasis can lead to increased injury of cholangiocytes
due to prolonged membrane exposure. It has been demonstrated
that, at decreased pH levels, the penetration and accumulation of
bile salts into cholangiocytes increase7,8. The penetrating ability of
bile acids is largely determined by their protonation, and can be
determined by their pKa7. This increase in biliary acidity also
contributes to enhanced rates of apoptosis. It has also been
determined that bile acid uptake is inﬂuenced by the expression
of anion exchanger 2 (AE2)7,8. Higher rates of bile acid uptake and
toxicity are noted in the setting of decreased AE2 expression7.
These ﬁndings reﬂect the importance of the bicarbonate umbrella,
which produces a more alkaline environment at the cholangiocyte
apical membrane. It has been described as a glycocalyx composed
of a variety of substances, such as glycosphingolipids, proteogly-
cans, glycosylated proteins and glycosaminoglycans7. The secre-
tion of bicarbonate rich ﬂuid is mediated via conjugated UDCA by
the Cl/HCO3
 exchanger and AE2, in response to secretin acting
on the cholangiocyte18. However, this response is not found in
those with untreated PBC. Conjugated ursodeoxycholic acid has
been shown to promote secretin-stimulated hydrocholresis via
multiple mediators, including AE2, PKCα, PI3K, MEK, PKA,
intracellular Ca2þ and microtubules18. It has been shown, via
studies utilizing colchicine and biliary inhibitors, that this route is
highly dependent on microtubule polymerization18. Secretin alone
cannot stimulate hydrochloresis. For it to be effective, the bile-acid
pool must be maintained in a relatively homeostatic state. In
patients with PBC, secretin induced bicarbonate secretion is
diminished. When such patients are treated with UDCA, the
response to secretin is restored, allowing hydrochloresis to occur18.
Treatment with UDCA also improves the expression of AE2,
which is diminished in the setting of PBC. One report demon-
strated that hydrochloresis via the secretin induced UDCA path-
way requires conjugation of UDCA. When given orally, UDCA is
conjugated in hepatocytes as it reaches the liver via portal
circulation18. It can then reach the basolateral surface of cholan-
giocytes via enterohepatic circulation. It is important to note that a
combination of factors is required to increase bile ﬂow. One study
demonstrated that secretin, UDCA and taurine conjugated UDCA
were not individually able to enhance bile ﬂow, but were able to
do so when in combination with one another18. The cytoprotective
mechanisms of UDCA reﬂect the important role that it may play in
the prevention of cholestasis and treatment of cholangiopathies.
The bicarbonate umbrella has also been suggested as a target for
the treatment of cholangiopathies. Of particular interest is the fact
that fucosyltransferase 2, which is an enzyme known to be
responsible for maintenance of the biliary glycocalyx, has been
determined to be a susceptibility gene for primary sclerosing
cholangitis8. A study of bile acid sensitive ion channel (BASIC),
which is highly expressed in cholangiocytes, demonstrated that
UDCA is a potent activator of this channel. While further studies
are needed to better determine the role and cellular activities of
BASIC, the study suggested that it may act as a factor in the
therapeutic effects provided by UDCA25.6. Sphingosine 1-phosphate receptor 2 (S1PR2)
Although it is rare, cholangiocarcinoma, a primary neoplasm arising
from cholangiocytes, is the second most common primary hepatic
neoplasm2. Due to increasing incidence, targets for potential therapies
have become a particular area of interest. Most cases of cholangio-
carcinoma are sporadic, having no known risk factors associated.
Figure 2 Schematic representation of bile acid-activated intracellular
pathways involved in the sustenance of cholangiocarcinoma growth
and invasiveness. Reprinted with permission from Maroni et al.27.
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chronic cholestasis, such as choledocholithiasis, PSC, hepatolithiasis
and ﬂuke infestation of the biliary tract, are risk factors for the
development of cholangiocarcinoma. Conjugated bile acids increase
the expression of cyclooxygenase-2 (COX-2), an enzyme implicated
in a variety of cancers, via activation of epidermal growth factor
receptor (EGFR). Unlike free bile acids, conjugated bile acids
increase the activation of nuclear factor-kappa B (NF-κB), which is
associated with higher levels of interleukin-6 (IL-6) and COX-2
expression, both of which are implicated in enhanced growth and
apoptosis resistance in cholangiocarcinoma cells26. Studies have also
shown that, via activation of S1PR2, the growth and invasiveness of
cholangiocarcinoma can be sustained by conjugated bile acids26,27.
S1PR2 is a G-protein coupled receptor act via the sphingosine-1-
phosphate (S1P) ligand to exert both proliferative and anti-proliferative
effects in various tissues. This effect is cell-type speciﬁc. Levels of
S1PR2 are higher in human cholangiocarcinoma cells than in non-
tumor samples from the same source27. In cholangiocytes, S1PR2
enhances proliferation via activation of ERK1/2 and protein kinases B
(AKT). It has also been shown that TCA has the ability to activate
S1PR2, thereby enhancing the invasiveness of cholangiocarcinoma.
TCA is a hydrophilic bile acid, acting as the most potent stimulator of
cholangiocarcinoma cell growth. To further demonstrate the speciﬁc
effect of S1PR2 on cholangiocytes, JTE-013, a selective S1PR2
agonist, was utilized. It was shown, via utilization of TCA mediated
cholangiocarcinoma proliferation, that this antagonist blunted both
ERK1/2 and AKT levels, and reduced proliferation of cholangiocarci-
noma cell lines26. It has been hypothesized that conjugated bile acids
exert the aforementioned effects without ever actually entering the
cholangiocyte, and this, if true, could explain dysregulation of FXR
expression in the setting of cholangiocarcinoma26. Fig. 2 demonstrates
the diverse effects of bile acids on SIPR2 and EGFR. Further studies
are needed to determine the therapeutic potential of S1PR2 directed
treatments.
7. Conclusions
The role of cholangiocytes encompasses much more than initially
considered. Multiple studies have demonstrated ways in which
they may be targeted as a therapeutic option in the future. The
proper functioning of these cells is necessary to maintain biliary
homeostasis. This is underscored by the many detrimental effectsthat cholestasis has been proven to cause and is thought to cause.
Cholangiocytes are the site of many concerted signaling pathways,
which demonstrate effects throughout the body. TGR5 acts on
both inhibitory and stimulatory pathways in cholangiocytes in an
effort to regulate cellular proliferation and apoptosis. It also
mediates the immune response by inhibiting the secretion of
inﬂammatory cytokines. While it may provide beneﬁt in the ﬁeld
of cholangiopathies, its possible relationship to malignancies must
be studied further as its anti-apoptotic properties could contribute
to detrimental side effects. FXR plays a hepato-protective role by
helping to regulate bile acid synthesis. It has also been shown to
have the ability to enhance proliferation of both hepatocytes and
cholangiocytes and promote hepatic healing. The bicarbonate
umbrella provides a protective shield for cholangiocytes against
bile acids. Because secretion and absorption of bile acids are
highly connected to pH and protonation, this alkaline layer
protects cholangiocytes from the intracellular accumulation of
toxic bile acids. Ursodeoxycholic acid promotes the hydrochloresis
necessary to maintain the protective layer. It has also been shown
to have the ability to enhance bile ﬂow, which decreases toxicity
via decreasing biliary transit time. It is already considered the ﬁrst
line treatment in some cholangiopathies. While cholangiocytes
have been determined to have a very important role in many areas,
further research is required to reveal their signaling potential.
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